{
  "id": "fda_guidance_chunk_0714",
  "title": "Introduction - Part 714",
  "text": "percentage difference of these extremes from the standard is shown in column F. Finally, the range of animal weights that produced a conversion factor for a 60 kg human within 20 percent of the standard factor is shown in column G. The ±10 percent and ±20 percent intervals across the entire range of weights are graphically illustrated for rats in Table 5. Table 4: Effect of Body Weight on Human Equivalent Dose Conversionsa A B C D E F G Conversion Factorc Species Animal Weight Rangeb (kg) sm animal lg human lg animal sm human Standardd % Difference of Extremee from Standard ±20% Rangef for 60 kg Human (kg) M ouse 0.018-0.033 0.060 0.089 0.081 -22% 0.015-0.051 R at 0.090-0.400 0.106 0.213 0.162 -35% 0.123-0.420 R abbit 1.5-3.0 0.269 0.395 0.324 +22% 1.0-3.4 M onkey 1.5-4.0 0.319 0.435 0.324 +34% 1.0-3.4 Dog 6.5-13.0 0.437 0.641 0.541 -19% 4.7-16.2 a conversion factor = (Wanimal/Whuman)0.33 b human weight range used was 50-80 kg (110-176 lb) c HED in mg/kg equals animal dose in mg/kg multiplied by this value d See Table 1 e extreme from column C or D f range of animal weights that produced a calculated conversion factor within 20 percent of the standard factor (column E) when human weight was set at 60 kg Contains Nonbinding Recommendations Table 5: Human and Rat Body Weights Producing Body Surface Area Dose Conversion Factors Within 10 Percent and 20 Percent of the Standard Factor (0.162) EFFECT OF BODY WEIGHT ON BSA-CF HED = animal NOAEL· (Wanimal/Whuman)exp(1-b), b = 0.67 for mg/m2 conversion ± 10% 0.146-0.178 Standard conversion to mg/kg = 0.162 ± 20% 0.130-0.194 Human Body Weight (kg) Rat Body Weight (kg) 0.090 0.124 0.120 0.117 0.114 0.111 0.109 0.106 0.100 0.129 0.125 0.121 0.118 0.115 0.113 0.110 0.110 0.133 0.129 0.125 0.122 0.119 0.116 0.114 0.120 0.137 0.132 0.129 0.125 0.122 0.119 0.117 0.130 0.140 0.136 0.132 0.129 0.126 0.123 0.120 0.140 0.144 0.139 0.135 0.132 0.129 0.126 0.123 0.150 0.147 0.142 0.138 0.135 0.132 0.129 0.126 0.160 0.150 0.146 0.141 0.138 0.134 0.131 0.129 0.170 0.153 0.149 0.144 0.141 0.137 0.134 0.131 0.180 0.156 0.151 0.147 0.143 0.140 0.137 0.134 0.190 0.159 0.154 0.150 0.146 0.142 0.139 0.136 0.200 0.162 0.157 0.152 0.148 0.145 0.141 0.138 0.210 0.164 0.159 0.155 0.151 0.147 0.144 0.141",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 958272,
  "end_pos": 959808,
  "tokens": 512,
  "tags": [],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.733Z"
}